First Look, May 02, 2022 Tirzepatide Excites in Obesity Now Too, Says Lilly The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review ...

On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

The most common side effects include nausea, diarrhea, and decreased appetite. Mounjaro (tirzepatide) is prescribed to help manage blood sugar levels in adults with type 2 diabetes, along with a ...

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...